Glyde Bio is an immune-oncology startup that are exploiting the aberrantly glycosylated cancer proteome as a new and rich source of tumor neoantigens. Their aim is to mine the cancer glycome as a rich source of neoantigens for cancer immune-therapy. Glyde’s platform technologies of conjugate vaccines, applied immunology, glycobiology, and glycol-proteomics are driving the development of first generation clinical candidates and the discovery of new tumor-specific glycans for next generations cancer therapies. Since starting at Nest.Bio Labs, they have raised about $10M in fundraising.